FASENRA Regulatory Postmarketing Surveillance in Korea

Trial Identifier:	D3250R00043
Sponsor:	AstraZeneca
Start Date:	March 2022
Primary Completion Date:	March 2025
Study Completion Date:	March 2025
Condition:	Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
South Korea, South Korea	Gangneung-si, South Korea, South Korea
South Korea, South Korea	Suwon-si, South Korea, South Korea
South Korea, South Korea	Ulsan, South Korea, South Korea

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.